Target
HLA-A*02:01
4 abstracts
Abstract
Phase 1 dose-finding study to evaluate safety and tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma.Org: Centre for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, Department of Neurosurgery, LMU University Hospital, LMU Munich, Liège University Hospital, Department of Neurology and Wilhelm Sander-Therapy Unit, University Hospital Regensburg, Division of Clinical Neuro-Oncology, Department of Neurology, University Hospital Bonn,
Abstract
First-in-human study of 225actinium mti-201 (225Ac-MTI-201) in metastatic uveal melanoma (UM).Org: H. Lee Moffitt Cancer Center and Research Institute, Washington University School of Medicine in St Louis, Modulation Therapeutics,
Abstract
Survival outcomes associated with liver-directed therapies in patients with metastatic uveal melanoma.Org: Columbia University Irving Medical Center, New York, NY, USA, Herbert Irving Comprehensive Cancer Center, Northwell Health Cancer Institute,
Abstract
HLA discordance between blood and tumor: A treatment conundrum?Org: Sidney Kimmel Cancer Center at Thomas Jefferson University, Thomas Jefferson University, Philadelphia, PA,